De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review.
- Author:
Hanxu GUO
1
;
Chengqi JIN
2
;
Li DING
1
;
Jun XIE
3
;
Jing XU
1
;
Ruiliang WANG
1
;
Hong WANG
1
;
Changcheng GUO
1
;
Jiansheng ZHANG
4
;
Bo PENG
1
;
Xudong YAO
1
;
Jing YUAN
1
;
Bin YANG
1
Author Information
- Publication Type:Journal Article
- From: Chinese Medical Journal 2025;138(2):231-233
- CountryChina
- Language:English
